TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Since CD30 expression is also retained in R/R lymphoma, it is thought that a bicistronic CCR4CD30CAR-T product would be more potent mostly in CD30+ CTCL due to enhanced trafficking to the skin.